Declining incidence of candidemia in a tertiary inpatient pediatric population

Journal of Clinical Microbiology

Volumn 50, Issue 3, 2012, Pages 1048-1050

  Ota, Kaede V ^a,b   McGowan, Karin L ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; VORICONAZOLE;

ADOLESCENT; ADULT; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DOSE RESPONSE; FUNGUS ISOLATION; HOSPITAL PATIENT; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PEDIATRICS; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; TERTIARY HEALTH CARE;

ADOLESCENT; ANTIFUNGAL AGENTS; CANDIDA; CANDIDEMIA; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; HOSPITALS; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; INPATIENTS; MICROBIAL SENSITIVITY TESTS; RETROSPECTIVE STUDIES;

EID: 84857430263     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.06346-11     Document Type: Article

References (19)

1. Blyth CC, et al. 2009. Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients. Pediatrics 123:1360-1368.
2. CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard - third edition. CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
3. CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; third informational supplement. CLSI document M27-S3. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Dutta A, Palazzi DL. 2011. Candida non-albicans versus Candida albicans fungemia in the non-neonatal pediatric population. Pediatr. Infect. Dis. J. 30:664-668.
5. Garey KW, et al. 2006. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin. Infect. Dis. 43:25-31. (Pubitemid 43939072)
6. Haynes K. 2001. Virulence in Candida species. Trends Microbiol. 9:591-596. (Pubitemid 33135415)
7. Horn DL, et al. 2009. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin. Infect. Dis. 48:1695-1703.
8. Karlowicz MG, Hashimoto LN, Kelly RE, Jr, Buescher ES. 2000. Should central venous catheters be removed as soon as candidemia is detected in neonates? Pediatrics 106:E63.
9. Levy I, Rubin LG, Vasishta S, Tucci V, Sood SK. 1998. Emergence of Candida parapsilosis as the predominant species causing candidemia in children. Clin. Infect. Dis. 26:1086-1088. (Pubitemid 28215469)
10. MacDonald L, Baker C, Chenoweth C. 1998. Risk factors for candidemia in a children's hospital. Clin. Infect. Dis. 26:642-645. (Pubitemid 28155013)
11. Morrell M, Fraser VJ, Kollef MH. 2005. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob. Agents Chemother. 49:3640-3645. (Pubitemid 41233011)
12. Neu N, et al. 2009. Epidemiology of candidemia at a children's hospital, 2002 to 2006. Pediatr. Infect. Dis. J. 28:806-809.
13. O'Grady NP, et al. 2011. Guidelines for the prevention of intravascular catheter-related infections, 2011. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/hicpac/pdf/guidelines/bsi-guidelines-2011.pdf.
14. Ota KV, McGowan KL. 2011. Declining incidence of candidemia in a pediatric population, abstr 176, p 62. Abstr. 111th Gen. Meet. Am. Soc. Microbiol. American Society for Microbiology, Washington, DC.
15. Pappas PG, et al. 2003. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin. Infect. Dis. 37:634-643. (Pubitemid 37100802)
16. Pappas PG, et al. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
17. Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D. 2011. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Diagn. Microbiol. Infect. Dis. 71:252-259.
18. Pfaller MA, et al. 2011. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist. Updat. 14:164 -176.
19. Rex JH, et al. 1995. Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Clin. Infect. Dis. 21:994-996.